Nature Search

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy

George Coukos
Antonis Makrigiannakis
Katherine L Molnar-Kimber
Research24 May 2000
Cancer Gene Therapy

Volume: 7, P: 275-283
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts

Jessica Zucman
Olivier Delattre
Gilles Thomas
Research01 Aug 1993
Nature Genetics

Volume: 4, P: 341-345
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

Coukos and colleagues conduct a phase 1 study to evaluate the benefit of adoptive transfer of ex vivo-expanded, vaccine-primed T cells in patients with ovarian cancer—a cancer type that often does not respond to immune checkpoint blockade.

Sara Bobisse
Valentina Bianchi
George Coukos
Research21 Sept 2023
Nature Cancer

Volume: 4, P: 1410-1417
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes

Signaling and transcriptional regulation of MDSC activity remains largely undefined. Here the authors show that monocytic MDSC immunosuppression is triggered by c-FLIP and requires NFκB, implicate this axis in cancer prognosis and response to therapy, and employ ectopic FLIP to treat immunopathology.

Alessandra Fiore
Stefano Ugel
Vincenzo Bronte
ResearchOpen Access05 Dec 2018
Nature Communications

Volume: 9, P: 1-13
Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene

Toshiyuki Sakai
Naoko Ohtani
Thaddeus P. Dryja
Research05 Sept 1991
Nature

Volume: 353, P: 83-86
Sensitive and frequent identification of high avidity neo-epitope specific CD8⁺ T cells in immunotherapy-naive ovarian cancer

Epithelial ovarian cancer (EOC) has low mutational load. Here the authors analyze circulating and tumor-infiltrating lymphocytes (TILs) from 19 EOC patients and report frequent recovery of neo-antigen-reactive T cells from both compartments but with distinct TCR repertoires that have higher affinity in TILs.

Sara Bobisse
Raphael Genolet
Alexandre Harari
ResearchOpen Access15 Mar 2018
Nature Communications

Volume: 9, P: 1-10
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

The immunogenicity of peptides is believed to be determined by their high-affinity binding to MHC I. Here authors show that low-affinity MHC I-peptide interactions are also able to trigger robust T cell response and anti-tumour immunity in vivo.

Hakimeh Ebrahimi-Nik
Marmar Moussa
Pramod K. Srivastava
ResearchOpen Access05 Nov 2021
Nature Communications

Volume: 12, P: 1-11
Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity

Organoid avatars of colorectal cancer and its microenvironment model immune interactions and drug efficacy.

L. Francisco Lorenzo-Martín
Nicolas Broguiere
Matthias P. Lutolf
Research02 Jul 2024
Nature Biotechnology

Volume: 43, P: 727-736
Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains

Synthetic transcriptional repressors are engineered from natural DNA-binding domains.

Thomas E. Speltz
Zeyu Qiao
Raymond E. Moellering
Research27 Oct 2022
Nature Biotechnology

Volume: 41, P: 541-551
Structural dissimilarity from self drives neoepitope escape from immune tolerance

Structural and biophysical approaches suggest that structural preorganization is important for triggering endogenous CD8⁺ T cells and escape from immune tolerance, as demonstrated by a single nonsynonymous mutation in an ovarian cancer neoepitope

Jason R. Devlin
Jesus A. Alonso
Brian M. Baker
Research17 Aug 2020
Nature Chemical Biology

Volume: 16, P: 1269-1276
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results

Preliminary findings in seven patients with mismatch repair-proficient metastatic colorectal cancer who were treated in the context of a phase 2 trial show that adoptive transfer of autologous peripheral blood T lymphocytes that were retrovirally transduced with personalized neoantigen-reactive T cell receptors can be safe and induce early clinical responses.

Maria Parkhurst
Stephanie L. Goff
Steven A. Rosenberg
Research11 Jul 2024
Nature Medicine

Volume: 30, P: 2586-2595
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Tyler J Curiel
George Coukos
Weiping Zou
Research22 Aug 2004
Nature Medicine

Volume: 10, P: 942-949
IgA transcytosis and antigen recognition govern ovarian cancer immunity

In patients with high-grade serous ovarian cancer, robust and protective humoral responses are dominated by B-cell-derived polyclonal IgA that binds to polymeric IgA receptors that are universally expressed on ovarian cancer cells.

Subir Biswas
Gunjan Mandal
Jose R. Conejo-Garcia
ResearchOpen Access03 Feb 2021
Nature

Volume: 591, P: 464-470
Ovarian cancer mutational processes drive site-specific immune evasion

Multi-modal analysis of genomically unstable ovarian tumours characterizes the contribution of anatomical sites and mutational processes to evolutionary phenotypic divergence and immune resistance mechanisms.

Ignacio Vázquez-García
Florian Uhlitz
Sohrab P. Shah
ResearchOpen Access14 Dec 2022
Nature

Volume: 612, P: 778-786
The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells

L Sepp-Lorenzino
A Balog
N Rosen
Research22 Feb 1999
Prostate Cancer and Prostatic Diseases

Volume: 2, P: 41-52
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

This Opinion article outlines a set of research priorities, based on discussions held at the 2015 Helene Harris Memorial Trust Ovarian Cancer Action meeting, that the authors believe will reduce incidence and improve outcomes for women with high-grade serous ovarian cancer.

David D. Bowtell
Steffen Böhm
Frances R. Balkwill
Reviews23 Oct 2015
Nature Reviews Cancer

Volume: 15, P: 668-679
A metabolite-derived protein modification integrates glycolysis with KEAP1–NRF2 signalling

Inhibition of the glycolytic enzyme PGK1 using a small molecular probe reveals a molecular link between glycolysis and the KEAP1–NRF2 signalling cascade.

Michael J. Bollong
Gihoon Lee
Raymond E. Moellering
Research15 Oct 2018
Nature

Volume: 562, P: 600-604
Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids

Devanjali Dutta
L. Francisco Lorenzo-Martín
Matthias P. Lutolf
ResearchOpen Access14 Aug 2024
npj Precision Oncology

Volume: 8, P: 1-7
Control of human mesothelin-expressing tumors by DNA vaccines

C-L Chang
T-C Wu
C-F Hung
Research21 Jun 2007
Gene Therapy

Volume: 14, P: 1189-1198
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

A L Cesne
I Judson
J-Y Blay
ResearchOpen Access10 Sept 2013
British Journal of Cancer

Volume: 109, P: 1717-1724
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Janos L. Tanyi
Cheryl L.-L. Chiang
Lana E. Kandalaft
ResearchOpen Access15 Mar 2021
npj Vaccines

Volume: 6, P: 1-14
Interrogating open issues in cancer precision medicine with patient-derived xenografts

This Opinion article discusses progress and challenges in using patient-derived xenograft (PDX) models in cancer precision medicine. It is primarily co-authored by members of the EurOPDX Consortium and as such highlights the merits of shared PDX resources.

Annette T. Byrne
Denis G. Alférez
Livio Trusolino
Reviews20 Jan 2017
Nature Reviews Cancer

Volume: 17, P: 254-268
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice

C-F Hung
Y-C Tsai
T-C Wu
Research17 Aug 2006
Gene Therapy

Volume: 14, P: 20-29
Attitudes towards the older patients with spinal cord injury among registered nurses: a cross-sectional observational study

J C Furlan
B C Craven
M G Fehlings
Research14 Apr 2009
Spinal Cord

Volume: 47, P: 674-680
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Janos L. Tanyi
Cheryl L.-L. Chiang
Lana E. Kandalaft
Amendments and CorrectionsOpen Access04 May 2021
npj Vaccines

Volume: 6, P: 1
Bystander T cells in cancer immunology and therapy

Wells and colleagues discuss emerging insights into bystander T cells, including analytical methods, the role of bystander T cell subtypes in tumor immunology and the potential ways that these cells can be leveraged to improve cancer immunotherapy.

Stefanie L. Meier
Ansuman T. Satpathy
Daniel K. Wells
Reviews28 Feb 2022
Nature Cancer

Volume: 3, P: 143-155
Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines

M C Courrèges
F Benencia
G Coukos
Research02 Sept 2005
Cancer Gene Therapy

Volume: 13, P: 182-193

Search

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy

EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts

A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes

Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene

Sensitive and frequent identification of high avidity neo-epitope specific CD8⁺ T cells in immunotherapy-naive ovarian cancer

Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity

Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains

Structural dissimilarity from self drives neoepitope escape from immune tolerance

Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

IgA transcytosis and antigen recognition govern ovarian cancer immunity

Ovarian cancer mutational processes drive site-specific immune evasion

The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

A metabolite-derived protein modification integrates glycolysis with KEAP1–NRF2 signalling

Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids

Control of human mesothelin-expressing tumors by DNA vaccines

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice

Attitudes towards the older patients with spinal cord injury among registered nurses: a cross-sectional observational study

Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Bystander T cells in cancer immunology and therapy

Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines

Search

Quick links

Search

Filter By:

Search

Quick links